Chinese biopharmaceutical company
Appears in 1 story
Engineered ivonescimab; retains rights in China
AstraZeneca is paying $2 billion for roughly 12% of Summit Therapeutics, betting that a next-generation lung-cancer drug can anchor its antibody-drug conjugate portfolio. The investment funds a clinical collaboration pairing Summit's ivonescimab with AstraZeneca's experimental ADC, Sone-Ve, in gastrointestinal cancers.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
